| pubmed-article:21033237 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21033237 | lifeskim:mentions | umls-concept:C0524910 | lld:lifeskim |
| pubmed-article:21033237 | lifeskim:mentions | umls-concept:C0348024 | lld:lifeskim |
| pubmed-article:21033237 | lifeskim:mentions | umls-concept:C0280274 | lld:lifeskim |
| pubmed-article:21033237 | pubmed:issue | 101 | lld:pubmed |
| pubmed-article:21033237 | pubmed:dateCreated | 2010-10-29 | lld:pubmed |
| pubmed-article:21033237 | pubmed:abstractText | Thyroid disorders are common dysfunctions during HCV infection and IFN-therapy. The aim of the study was to evaluate the general risk of thyroid disorders' development in chronic HCV-infected patients and their possible relationship with HCV genotype, type of used IFN-alpha and viral response. | lld:pubmed |
| pubmed-article:21033237 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21033237 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21033237 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21033237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21033237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21033237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21033237 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21033237 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21033237 | pubmed:issn | 0172-6390 | lld:pubmed |
| pubmed-article:21033237 | pubmed:author | pubmed-author:PanasiukAnato... | lld:pubmed |
| pubmed-article:21033237 | pubmed:author | pubmed-author:FlisiakRobert... | lld:pubmed |
| pubmed-article:21033237 | pubmed:author | pubmed-author:DabrowskaMagd... | lld:pubmed |
| pubmed-article:21033237 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21033237 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:21033237 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21033237 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21033237 | pubmed:pagination | 826-31 | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:meshHeading | pubmed-meshheading:21033237... | lld:pubmed |
| pubmed-article:21033237 | pubmed:articleTitle | Thyroid dysfunction in antiviral therapy of chronic hepatitis C. | lld:pubmed |
| pubmed-article:21033237 | pubmed:affiliation | Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 14 Zurawia Str, 15-540 Bialystok, Poland. | lld:pubmed |
| pubmed-article:21033237 | pubmed:publicationType | Journal Article | lld:pubmed |
